The Human CEO Podcast, Helen Springford PodBean, January 2021 Focusing on approach to leadership, challenges faced and how to overcome them, also asking what it takes to be a good leader. “I get a lot of very positive feedback from my emails that I send out saying they really appreciate […]
In the Media
In a Medidata survey conducted in April 2020, nearly 70% of investigative site personnel indicated that COVID-19 affected their ability to conduct ongoing studies and 78% believed that the pandemic impacted their ability to initiate new trials.2 And yet, according to a report released by Greenphire in October 2020, patient […]
Some time ago, a survey was conducted on clinical trial professionals to determine what concerns worried the industry most. Experts were consulted from far and wide within pharmaceutical company sponsors, contract research organisations, site representatives and vendors. Despite all the great work by these collective groups, an overwhelming number of studies fail for the simple reason, that not […]
By Jessica Zeigler, Head of US Proposals When Jessica took a break from her career to devote her time to supporting her daughter Amelia, who has NOD2-associated autoinflammatory disease, she never expected that her unique insight into rare disease would lead her to a new role as in proposals at […]
CEO Series, Helen Springford Rare Revolution, August 2020 An interview conducted by Rare Revolution (RR) to Helen Springford (HS). Exploring Helen’s past, present and future, her aims for Illingworth Research in the coming years and advice to other embarking on a career in clinical research. caret-down caret-up caret-left caret-right RR: […]
The impact of the COVID-19 pandemic on clinical trials has been well chronicled in recent months, with new and ongoing studies targeting a number of diseases, particularly chronic conditions, being hit hard by reductions in patient participation. This has shifted fundamental approaches in clinical operations, with some pharma sponsors turning to digital […]
Juliet Hulse at Illingworth Research Group explores the threat posed by Covid-19 on global rare disease clinical trial programmes, and the opportunities that may arise from this dynamic global situation.